

With Gratitude to Alan's Legacy

Respectfully prepared for Sophia Bell

On behalf of the Children's Hospital of Philadelphia (CHOP), CHOP's Center for Childhood Cancer Research (CCCR), and the Cellular Immunotherapy program, thank you and Alan's Legacy for your decade of unwavering support for our research efforts. Your dedication has helped CHOP achieve remarkable milestones, advance breakthroughs, and make a lasting difference to the field and the patients who benefit from these treatments.

Like last year, CHOP's pediatric cancer program is ranked among the top in the nation, according to *U.S. News & World Report*. In addition to this achievement, CHOP has continued to work towards advancing its translational research through the Immunotherapy Program.

At CHOP, our goal is to bring the most effective treatments to the most patients, as quickly as possible.

CHOP doctors and researchers are leading advances in developing effective immunotherapies for pediatric cancer and other disorders of the blood and immune system. This year, CHOP:

- <u>Treated its 500th CAR T Patient in July</u> (with more than 20,000 pediatric patients being treated worldwide),
- Developed <u>a new computational platform</u> in partnership with the University of California, Los Angeles (UCLA) that is capable of discovering tumor antigens from alternative RNA splicing, expanding the pool of cancer immunotherapy targets, and
- Hosting a number of <u>immunotherapy clinical trials and pilot studies</u> to advance the field of immunotherapy and better treat patients.

Thank you again for your longstanding support. We are filled with immense gratitude for your trust and belief in this work. We look forward to the Immunotherapy Program's journey ahead and are grateful to have you as a valued partner for these future breakthroughs.

Thank you

Samantha Camp
Assistant Director, Foundation Relations
camps@chop.edu | (908) 720-2602